併用抗体療法市場：タイプ別、適応症別、投与経路別、流通チャネル別、最終用途別-2025～2030年の世界予測

併用抗体療法市場は、2023年に2,093億7,000万米ドルと評価され、2024年には2,315億5,000万米ドルに達すると予測され、CAGR 9.30%で成長し、2030年には3,901億8,000万米ドルに達すると予測されています。

併用抗体療法は、様々な疾患、特にがん、自己免疫疾患、感染症を治療するために、異なる抗原やエピトープを標的とする2つ以上のモノクローナル抗体を使用することを指します。このアプローチは、治療効果を高め、耐性を克服し、病理学的標的に対する多面的な攻撃を提供することを目的としています。併用抗体療法の必要性は、単剤治療が困難な複雑な疾患がますます蔓延していることから生じています。併用療法は、相乗効果の増強、薬剤耐性の低減、奏効率の改善を可能にし、それによって重要なアンメット・メディカル・ニーズを満たすことができます。その用途は、腫瘍増殖に関与する複数の経路を標的とする腫瘍学、関節リウマチのような慢性疾患、COVID-19のような感染症など多岐にわたります。最終用途の範囲には、先進的治療ソリューションの開発に従事する病院、クリニック、研究機関が含まれます。

併用抗体療法市場の成長は、慢性疾患や生活習慣病の有病率の上昇と相まって、バイオテクノロジーの進歩や製薬セクターにおける研究開発費の増加が主要要因となっています。治療用抗体のパイプラインの拡大と医療支出の増加が、市場をさらに活性化させています。最近では、個別化医療と精密治療の可能性が機会として浮上しています。包括的な患者データ分析を活用して、オーダーメイドの併用療法を開発すれば、治療成績が大幅に向上する可能性があります。企業への提言としては、イノベーションを加速するためのパートナーシップや共同研究への投資、調査方法を合理化するための技術の導入などが挙げられます。

併用抗体療法市場は、その有望な可能性にもかかわらず、高い開発コスト、規制上の課題、複雑な生産プロセス、免疫学的副作用のリスクなどの限界に直面しています。探索すべき革新的なセグメントとしては、抗体の選択と組み合わせを最適化するための人工知能の利用、新規の送達メカニズム、治療反応を予測するための予測モデリングなどが挙げられます。市場は急速な技術進歩と激しい競争を特徴としており、競争優位性を確保するためには機敏な戦略が必要となります。新規抗体と免疫系相互作用の継続的な研究は、このダイナミックで進化するセグメントで事業の成長を維持するために極めて重要です。

市場力学：急速に進化する併用抗体療法市場の主要市場洞察を公開

併用抗体療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のがん患者数の増加
  • 治療と患者の転帰を向上させるニーズの高まり
  • 薬剤耐性管理への利用
• 市場抑制要因
  • 併用抗体療法の高コストと複雑さ
• 市場機会
  • 併用抗体療法の進行中の調査と臨床検査
  • 個別化医療アプローチの新たな利用
• 市場課題
  • 併用抗体療法に関連する副作用

ポーターのファイブフォース：併用抗体療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、併用抗体療法市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：併用抗体療法市場における外部からの影響の把握

外部マクロ環境要因は、併用抗体療法市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：併用抗体療法市場における競合情勢の把握

併用抗体療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス併用抗体療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、併用抗体療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：併用抗体療法市場における成功への道筋を描く

併用抗体療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品上市、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でがん患者数が増加
    • 治療と患者の転帰を改善する必要性が高まる
    • 薬剤耐性管理への活用
  • 抑制要因
    • 併用抗体療法のコストと複雑さが高い
  • 機会
    • 併用抗体療法に関する進行中の研究と臨床検査
    • 個別化医療アプローチの新たな利用
  • 課題
    • 併用抗体療法に関連する悪影響
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 併用抗体療法市場：タイプ別

• イントロダクション
• 抗体薬剤複合体
• 二重特異性抗体
• 化学療法モノクローナル抗体

第7章 併用抗体療法市場：適応症別

• イントロダクション
• がん
  • 血液がん
  • 乳がん
  • 大腸がん
  • 肺がん
• HIV

第8章 併用抗体療法市場：投与経路別

• イントロダクション
• 経口
• 非経口

第9章 併用抗体療法市場：流通チャネル別

• イントロダクション
• 病院薬局
• オンライン薬局
• 小売薬局

第10章 併用抗体療法市場：最終用途別

• イントロダクション
• 在宅医療
• 病院
• 専門センター

第11章 南北アメリカの併用抗体療法市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の併用抗体療法市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの併用抗体療法市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Argenx SE
• AstraZeneca PLC
• Atreca, Inc.
• Bayer AG
• BeiGene, Ltd.
• Biogen Inc.
• BioNTech SE
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• CStone Pharmaceuticals
• Eli Lilly and Company
• Five Prime Therapeutics, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• I-Mab Biopharma Co., Ltd.
• IGM Biosciences, Inc.
• Incyte Corporation
• Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc.
• Jazz Pharmaceuticals plc
• Kyowa Kirin Co., Ltd.
• MacroGenics, Inc.
• Merck & Co., Inc.
• MorphoSys AG
• NBE-Therapeutics AG
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sutro Biopharma, Inc.
• Takeda Pharmaceutical Company Limited
• Trillium Therapeutics Inc.
• Xencor, Inc.
• Zymeworks Inc.

LIST OF FIGURES

• FIGURE 1. COMBINATION ANTIBODY THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. COMBINATION ANTIBODY THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. COMBINATION ANTIBODY THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. COMBINATION ANTIBODY THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. COMBINATION ANTIBODY THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. COMBINATION ANTIBODY THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CHEMOTHERAPY-MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY SPECIALTY CENTRES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 49. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 52. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. CANADA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 58. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 64. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 70. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 71. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 75. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 78. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 81. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 84. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 85. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. CHINA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 90. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 91. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. INDIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 93. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 96. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 102. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 105. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 108. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 114. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 117. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 120. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 129. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 132. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 138. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 141. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 144. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 150. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 154. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 156. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 157. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 160. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 161. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 163. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 166. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 169. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 172. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 175. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 178. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 181. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 184. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 187. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 190. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 193. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 194. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 195. ITALY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 196. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 199. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 202. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 204. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 205. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 208. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 211. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 214. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 217. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. POLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 220. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 223. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 224. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 225. QATAR COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 226. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 227. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 229. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 232. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 238. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 240. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 244. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 246. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 247. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 250. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 252. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 253. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 256. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 258. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 259. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 262. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 263. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 264. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 265. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 268. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 269. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 270. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 271. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 274. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
• TABLE 277. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM COMBINATION ANTIBODY THERAPY MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 280. COMBINATION ANTIBODY THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 281. COMBINATION ANTIBODY THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Combination Antibody Therapy Market was valued at USD 209.37 billion in 2023, expected to reach USD 231.55 billion in 2024, and is projected to grow at a CAGR of 9.30%, to USD 390.18 billion by 2030.

Combination antibody therapy refers to the use of two or more monoclonal antibodies to target different antigens or epitopes to treat various diseases, particularly cancer, autoimmune, and infectious diseases. This approach aims to enhance therapeutic efficacy, overcome resistance, and provide a multifaceted attack on pathological targets. The necessity for combination antibody therapy arises from the increasing prevalence of complex diseases that challenge single-agent treatments. Combination therapy allows for enhanced synergistic effects, reduced drug resistance, and improved response rates, thereby meeting critical unmet medical needs. Its application spans oncology, where it is used to target multiple pathways involved in tumor growth, as well as in chronic diseases like rheumatoid arthritis and infectious diseases like COVID-19. The end-use scope includes hospitals, clinics, and research institutes engaged in developing advanced therapeutic solutions.

The growth of the combination antibody therapy market is primarily driven by advancements in biotechnology and increased R&D spending in the pharmaceutical sector, coupled with a rising prevalence of chronic and lifestyle-associated diseases. An expanding pipeline of therapeutic antibodies and increasing healthcare expenditure further fuel the market. Lately, the potential for personalized medicine and precision treatment has emerged as an opportunity; leveraging comprehensive patient data analytics to develop tailored combination therapies could significantly enhance outcomes. Recommendations for companies include investing in partnerships and collaborations to accelerate innovation and adopting technology to streamline research processes.

Despite its promising potential, the combination antibody therapy market faces limitations such as high development costs, regulatory challenges, complex production processes, and the risk of adverse immunological responses. Innovative areas to explore include the use of artificial intelligence to optimize antibody selection and combination, novel delivery mechanisms, and predictive modeling to anticipate therapeutic responses. The market is characterized by rapid technological advancements and intense competition, necessitating agile strategies to secure a competitive edge. Continued research into novel antibodies and immune system interactions will be crucial for sustaining business growth in this dynamic and evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Combination Antibody Therapy Market

The Combination Antibody Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising number of cancer cases worldwide
  • Growing need to enhance treatment and patient outcomes
  • Utilization for drug resistance management
• Market Restraints
  • High cost and complexity of combination antibody therapy
• Market Opportunities
  • Ongoing research and clinical trials for combination antibody therapy
  • Emerging use of personalized medicine approach
• Market Challenges
  • Adverse effects associated with combination antibody therapy

Porter's Five Forces: A Strategic Tool for Navigating the Combination Antibody Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Combination Antibody Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Combination Antibody Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Combination Antibody Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Combination Antibody Therapy Market

A detailed market share analysis in the Combination Antibody Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Combination Antibody Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Combination Antibody Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Combination Antibody Therapy Market

A strategic analysis of the Combination Antibody Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Combination Antibody Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Argenx SE, AstraZeneca PLC, Atreca, Inc., Bayer AG, BeiGene, Ltd., Biogen Inc., BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CStone Pharmaceuticals, Eli Lilly and Company, Five Prime Therapeutics, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, I-Mab Biopharma Co., Ltd., IGM Biosciences, Inc., Incyte Corporation, Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc., Jazz Pharmaceuticals plc, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Merck & Co., Inc., MorphoSys AG, NBE-Therapeutics AG, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sutro Biopharma, Inc., Takeda Pharmaceutical Company Limited, Trillium Therapeutics Inc., Xencor, Inc., and Zymeworks Inc..

Market Segmentation & Coverage

This research report categorizes the Combination Antibody Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Antibody-Drug Conjugates, Bispecific Antibodies, and Chemotherapy-Monoclonal Antibodies.
• Based on Indication, market is studied across Cancer and HIV. The Cancer is further studied across Blood Cancer, Breast Cancer, Colorectal Cancer, and Lung Cancer.
• Based on Route of Administration, market is studied across Oral and Parenteral.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on End-Use, market is studied across Homecare, Hospitals, and Specialty Centres.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising number of cancer cases worldwide
    • 5.1.1.2. Growing need to enhance treatment and patient outcomes
    • 5.1.1.3. Utilization for drug resistance management
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and complexity of combination antibody therapy
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research and clinical trials for combination antibody therapy
    • 5.1.3.2. Emerging use of personalized medicine approach
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with combination antibody therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Combination Antibody Therapy Market, by Type

• 6.1. Introduction
• 6.2. Antibody-Drug Conjugates
• 6.3. Bispecific Antibodies
• 6.4. Chemotherapy-Monoclonal Antibodies

7. Combination Antibody Therapy Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
  • 7.2.1. Blood Cancer
  • 7.2.2. Breast Cancer
  • 7.2.3. Colorectal Cancer
  • 7.2.4. Lung Cancer
• 7.3. HIV

8. Combination Antibody Therapy Market, by Route of Administration

• 8.1. Introduction
• 8.2. Oral
• 8.3. Parenteral

9. Combination Antibody Therapy Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Combination Antibody Therapy Market, by End-Use

• 10.1. Introduction
• 10.2. Homecare
• 10.3. Hospitals
• 10.4. Specialty Centres

11. Americas Combination Antibody Therapy Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Combination Antibody Therapy Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Combination Antibody Therapy Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Argenx SE
• 4. AstraZeneca PLC
• 5. Atreca, Inc.
• 6. Bayer AG
• 7. BeiGene, Ltd.
• 8. Biogen Inc.
• 9. BioNTech SE
• 10. Boehringer Ingelheim International GmbH
• 11. Bristol Myers Squibb Company
• 12. CStone Pharmaceuticals
• 13. Eli Lilly and Company
• 14. Five Prime Therapeutics, Inc.
• 15. Gilead Sciences, Inc.
• 16. GlaxoSmithKline plc
• 17. I-Mab Biopharma Co., Ltd.
• 18. IGM Biosciences, Inc.
• 19. Incyte Corporation
• 20. Janssen Pharmaceuticals, Inc. by Johnson & Johnson Service Inc.
• 21. Jazz Pharmaceuticals plc
• 22. Kyowa Kirin Co., Ltd.
• 23. MacroGenics, Inc.
• 24. Merck & Co., Inc.
• 25. MorphoSys AG
• 26. NBE-Therapeutics AG
• 27. Novartis AG
• 28. Pfizer Inc.
• 29. Regeneron Pharmaceuticals, Inc.
• 30. Roche Holding AG
• 31. Sanofi S.A.
• 32. Sutro Biopharma, Inc.
• 33. Takeda Pharmaceutical Company Limited
• 34. Trillium Therapeutics Inc.
• 35. Xencor, Inc.
• 36. Zymeworks Inc.